secwatch / observer
8-K/A filed October 9, 2024, 7:59 PM ET ticker BRGX CIK 0001593184
M&A confidence high sentiment negative materiality 0.75

BIOREGENX, INC. (BRGX): M&A transaction — BioRegenx completes reverse merger; posts $3.6M net loss in 2023 with going concern doubt

BIOREGENX, INC.

item 2.01item 3.02item 5.01item 5.02item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gary Hennerberg

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
Appointed

Gary Hennerberg

Secretary
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
Gary Hennerberg – Secretary
Appointed

Jody Walker

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
Appointed

Robert Doran

Executive Vice President
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
Robert Doran – Executive Vice President
Appointed

Sherri Adams

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
Appointed

Sherri Adams

Chief Operating Officer
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
Sherri Adams – Chief Operating Officer
Appointed

Robert Doran

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
Departed

Thomas Powers

Other Named Officer
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant
Appointed (interim)

William Resides

Interim Financial Officer
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
William Resides – Chief Executive Officer, Interim Financial Officer
Appointed

Suzanne Bird

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
Departed

Raymond Firth

Other Named Officer
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant
Appointed

William Resides

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
Appointed

William Resides

Chief Executive Officer
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
William Resides – Chief Executive Officer, Interim Financial Officer
Departed

Raymond Firth

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
Effective March 8, 2024, Raymond Firth resigned as a director of the Registrant
Appointed

Gary Kiss

Director
BRGX · BIOREGENX, INC.
Effective
2024-03-08
Filed
October 9, 2024, 7:59 PM ET
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Hennerberg was appointed as Director at BIOREGENX, INC..

Action
appointed
Role
Director
Exact text from the filing
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Hennerberg was appointed as Secretary at BIOREGENX, INC..

Action
appointed
Role
Secretary
Exact text from the filing
Gary Hennerberg – Secretary
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jody Walker was appointed as Director at BIOREGENX, INC..

Action
appointed
Role
Director
Exact text from the filing
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Doran was appointed as Executive Vice President at BIOREGENX, INC..

Action
appointed
Role
Executive Vice President
Exact text from the filing
Robert Doran – Executive Vice President
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sherri Adams was appointed as Director at BIOREGENX, INC..

Action
appointed
Role
Director
Exact text from the filing
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sherri Adams was appointed as Chief Operating Officer at BIOREGENX, INC..

Action
appointed
Role
Chief Operating Officer
Exact text from the filing
Sherri Adams – Chief Operating Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Doran was appointed as Director at BIOREGENX, INC..

Action
appointed
Role
Director
Exact text from the filing
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Powers resigned as other_named_officer at BIOREGENX, INC..

Action
resigned
Exact text from the filing
Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

William Resides was appointed as Interim Financial Officer at BIOREGENX, INC..

Action
appointed
Role
Interim Financial Officer
Exact text from the filing
William Resides – Chief Executive Officer, Interim Financial Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Suzanne Bird was appointed as Director at BIOREGENX, INC..

Action
appointed
Role
Director
Exact text from the filing
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Raymond Firth resigned as other_named_officer at BIOREGENX, INC..

Action
resigned
Exact text from the filing
Effective March 8, 2024, Raymond Firth and Thomas Powers resigned as officers of the Registrant
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

William Resides was appointed as Director at BIOREGENX, INC..

Action
appointed
Role
Director
Exact text from the filing
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

William Resides was appointed as Chief Executive Officer at BIOREGENX, INC..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
William Resides – Chief Executive Officer, Interim Financial Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Raymond Firth resigned as director at BIOREGENX, INC..

Action
resigned
Exact text from the filing
Effective March 8, 2024, Raymond Firth resigned as a director of the Registrant
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Kiss was appointed as Director at BIOREGENX, INC..

Action
appointed
Role
Director
Exact text from the filing
the following directors were appointed to join Thomas Powers on the Board of Directors: William Resides Robert Doran Sherri Adams Gary Hennerberg Suzanne Bird Jody Walker Gary Kiss
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BIOREGENX, INC.: Filed Certificate of Designation to ratify creation and issuance of 5,000,000 Series A preferred shares with voting rights of 2,500 votes per share (effective 2024-03-14).

Change
charter amendment
Effective
2024-03-14
Exact text from the filing
Effective March 14, 2024, the Registrant filed a Certificate of Designation (and subsequently, a Certificate of Correction) curing the 2013 creation of the Series A preferred shares and ratifying the issuances of 5,000,000 Series A preferred shares in 2013 which were retired pursuant to the terms of the merger. Each Series A preferred share has voting rights of 2,500 votes per Series A preferred share.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BIOREGENX, INC.: Increased authorized common stock to 1.5 billion shares and changed company name to BioRegenx, Inc (effective 2024-03-08).

Change
charter amendment
Effective
2024-03-08
Exact text from the filing
Effective March 8, 2024, the Registrant filed an Amendment to the Articles of Incorporation which increased the authorized common stock to One Billion Five Hundred Thousand (1,500,000,000) common shares. Additionally, the name of the Registrant was changed to BioRegenx, Inc.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

BIOREGENX, INC. underwent a change of control involving BioRegenx, Inc. for 851,977,296 common shares and 3,800 Series A preferred shares of the Registrant which represented 90.0% of the voting securities of the Registrant (closed 2024-03-08).

Action
change of control
Counterparty
BioRegenx, Inc.
Consideration
851,977,296 common shares and 3,800 Series A preferred shares of the Registrant which represented 90.0% of the voting securities of the Registrant
Closing
2024-03-08
Exact text from the filing
The name of the Registrant was changed to BioRegenx, Inc. Pursuant to the merger, all of the issued and outstanding BioRegenx common and preferred shares were exchanged for 851,977,296 common shares and 3,800 Series A preferred shares of the Registrant which represented 90.0% of the voting securities of the Registrant. Concurrently, holder(s) of the Registrant’s
View on SEC.gov

Browse all governance changes →

BIOREGENX, INC. filing history →

Source: SEC EDGAR
accession 0001683168-24-007019
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.